Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
Valsamo Anagnostou(Johns Hopkins University), Victor E. Velculescu(Johns Hopkins University), Benjamin Levy(Johns Hopkins University), Julie R. Brahmer(Johns Hopkins University), Matthew D. Hellmann(AstraZeneca (United States)), Edward Gabrielson(Johns Hopkins University), Rachel Karchin(University of Baltimore), Janis M. Taube(Bloomberg (United States)), Peter B. Illei(Johns Hopkins University), Doreen N. Palsgrove(Southwestern Medical Center), Jarushka Naidoo(Sidney Kimmel Comprehensive Cancer Center), I.K. Ashok Sivakumar(Johns Hopkins University), James R. White(Resphera Biosciences), Christos Georgiades(Johns Hopkins University), Lamia Rhymee(Johns Hopkins University), Kristen A. Marrone(Johns Hopkins University), Patrick M. Forde(Sidney Kimmel Comprehensive Cancer Center), Carolyn Hruban(Johns Hopkins University), Christine L. Hann(Johns Hopkins University), Jennifer L. Sauter(Memorial Sloan Kettering Cancer Center), Robert B. Scharpf(Johns Hopkins University), Daniel C. Bruhm(Johns Hopkins University), Drew M. Pardoll(Bloomberg (United States)), Alessandro Leal(Johns Hopkins University), Tricia R. Cottrell(Queen's University), Josephine Feliciano(Sidney Kimmel Comprehensive Cancer Center), Vilmos Adleff(Johns Hopkins University), Jillian Phallen(Johns Hopkins University), Noushin Niknafs(Johns Hopkins University), Qing Kay Li(Johns Hopkins University), Kellie N. Smith(Bloomberg (United States)), James M. Isbell(Memorial Sloan Kettering Cancer Center), Jamie E. Chaft(Memorial Sloan Kettering Cancer Center), Franco Verde(Bloomberg (United States)), Malcolm V. Brock(Johns Hopkins University), Samuel Rosner(State University of New York)
Cited by 313
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Cancer Genome Landscapes
|Science|2013|8k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k